ValuEngine upgraded shares of Cerus (NASDAQ:CERS) from a sell rating to a hold rating in a report published on Wednesday, March 14th.
Several other equities research analysts also recently weighed in on the company. Robert W. Baird reissued a buy rating and issued a $5.00 price target on shares of Cerus in a report on Friday, December 1st. Cantor Fitzgerald reissued a buy rating and issued a $5.00 price target on shares of Cerus in a report on Tuesday, January 23rd. BidaskClub downgraded Cerus from a sell rating to a strong sell rating in a report on Friday, December 29th. Zacks Investment Research downgraded Cerus from a hold rating to a sell rating in a report on Tuesday, January 30th. Finally, BTIG Research reaffirmed a hold rating on shares of Cerus in a report on Thursday, January 25th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $5.40.
NASDAQ CERS traded down $0.10 during trading on Wednesday, hitting $5.20. The company’s stock had a trading volume of 1,198,090 shares, compared to its average volume of 1,448,325. The company has a debt-to-equity ratio of 0.77, a quick ratio of 3.26 and a current ratio of 3.89. The company has a market cap of $673.90, a PE ratio of -9.29 and a beta of 1.75. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $5.85.
Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $16.20 million during the quarter, compared to the consensus estimate of $17.53 million. Cerus had a negative return on equity of 154.46% and a negative net margin of 139.06%. The company’s quarterly revenue was up 60.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) earnings per share. sell-side analysts predict that Cerus will post -0.43 earnings per share for the current fiscal year.
In related news, CEO William Mariner Greenman sold 7,735 shares of Cerus stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $4.80, for a total transaction of $37,128.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Laurence M. Corash purchased 150,011 shares of Cerus stock in a transaction that occurred on Thursday, March 15th. The shares were bought at an average price of $5.15 per share, with a total value of $772,556.65. Following the completion of the transaction, the insider now owns 1,462,580 shares of the company’s stock, valued at approximately $7,532,287. The disclosure for this purchase can be found here. Insiders have sold 14,381 shares of company stock valued at $69,685 in the last ninety days. Corporate insiders own 7.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas purchased a new position in Cerus during the fourth quarter valued at approximately $126,000. Premier Asset Management LLC purchased a new position in Cerus during the third quarter valued at approximately $348,000. Swiss National Bank increased its position in shares of Cerus by 16.0% in the fourth quarter. Swiss National Bank now owns 184,400 shares of the biotechnology company’s stock valued at $623,000 after buying an additional 25,500 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after buying an additional 184,076 shares in the last quarter. Finally, Bamco Inc. NY increased its position in shares of Cerus by 90.9% in the fourth quarter. Bamco Inc. NY now owns 1,071,000 shares of the biotechnology company’s stock valued at $3,620,000 after buying an additional 510,100 shares in the last quarter. Institutional investors own 51.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cerus (NASDAQ:CERS) Upgraded to Hold at ValuEngine” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/cerus-cers-raised-to-hold-at-valuengine.html.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.